• Login
    • Join
  • FOLLOW:
  • Subscribe Free
    • Magazine
    • eNewsletter
    Checkout
    • Magazine
    • News
    • Opinions
    • Top 30
    • Research
    • Supply Chain
    • Device Sectors
    • Directory
    • Events
    • Resources
    • Microsites
    • More
  • Magazine
  • News
  • Opinions
  • Top 30
  • Research
  • Supply Chain
  • Device Sectors
  • Directory
  • Events
  • Resources
  • Microsites
  • Current / Back Issues
    Features
    Editorial
    Digital Edition
    eNewsletter Archive
    Our Team
    Editorial Guidelines
    Reprints
    Subscribe Now
    Advertise Now
    Top Features
    Sensing Technology Drives the Future of Medical Care

    New and Developing Diabetes Technologies Offer 'Sweet Relief'

    Discussing Matters of Substance in Medtech Materials

    Medical Device Testers Are Caught Up in a Whirlwind

    6 Ways ERP Systems Help Medical Device Manufacturers Manage Risk and Profitability
    OEM News
    Supplier News
    Service / Press Releases
    Online Exclusives
    Press Releases
    People in the News
    Product & Service Releases
    Supplier News
    Medtech Makers
    Technical Features
    International News
    Videos
    Product & Service Releases
    Live From Shows
    Regulatory
    Financial/Business
    Top News
    Relay Robotics Adds Three Executives to its Product Team

    FDA Clears Atalante Hands-Free Self-Balancing Device

    Kerecis Debuts New Fish-Skin Burn Products

    Accumold Compliments its Tech Capability With Micro AM

    Abbott's CardioMEMS HF System Helps Manage Heart Failure
    From the Editor
    Blogs
    Guest Opinions
    Top Opinions
    Sensing Technology Drives the Future of Medical Care

    New and Developing Diabetes Technologies Offer 'Sweet Relief'

    Discussing Matters of Substance in Medtech Materials

    Medical Device Testers Are Caught Up in a Whirlwind

    6 Ways ERP Systems Help Medical Device Manufacturers Manage Risk and Profitability
    Top 30 Medical Device Companies
    Market Data
    White Papers
    Top Research
    CR-SOP Neurotechnology Helps to Achieve ‘Sound’ Sleep

    Inside the Hospital Value Analysis Committee

    Face Time: Why Getting Engineers Out of the Lab Is Good for Business

    Common Paratubing Pitfalls and How to Avoid Them

    During Times of Uncertainty, Create Business Value with an Optimized Workforce
    3D/Additive Manufacturing
    Contract Manufacturing
    Electronics
    Machining & Laser Processing
    Materials
    Molding
    Packaging & Sterilization
    R&D & Design
    Software & IT
    Testing
    Tubing & Extrusion
    Cardiovascular
    Diagnostics
    Digital Health
    Neurological
    Patient Monitoring
    Surgical
    Orthopedics
    All Companies
    Categories
    Company Capabilities
    Add New Company
    Outsourcing Directory
    NDH Medical Inc.

    Cirtec Medical

    Arthur G. Russell Co. Inc., The

    Providence Enterprise USA Inc.

    Forefront Medical Technology
    MPO Summit
    Industry Events
    Webinars
    Live From Show Event
    Industry Associations
    Videos
    Career Central
    eBook
    Slideshows
    Top Resources
    3D Printing Medical Devices Revolutionized Manufacturing

    5 Current Trends in Medical Device Security

    How Advanced Sensors Improve Design & Functionality of Respiratory Care Equipment

    Sourcing Silicone Parts: Injection Mold or 3D Print?

    Cybersecurity in Healthcare: Getting on the Right Track
    Companies
    News Releases
    Product Releases
    Press Releases
    Product Spec Sheets
    Service Releases
    Case Studies
    White Papers
    Brochures
    Videos
    Outsourcing Directory
    NDH Medical Inc.

    Cirtec Medical

    Arthur G. Russell Co. Inc., The

    Providence Enterprise USA Inc.

    Forefront Medical Technology
    • Magazine
      • Current/Back Issues
      • Features
      • Editorial
      • Columns
      • Digital Editions
      • Subscribe Now
      • Advertise Now
    • News
    • Directory
      • All Companies
      • ALL CATEGORIES
      • Industry Associations
      • Company Capabilities
      • Add Your Company
    • Supply Chain
      • 3D/Additive Manufacturing
      • Contract Manufacturing
      • Electronics
      • Machining & Laser Processing
      • Materials
      • Molding
      • Packaging & Sterilization
      • R&D & Design
      • Software & IT
      • Testing
      • Tubing & Extrusion
    • Device Sectors
      • Cardiovascular
      • Diagnostics
      • Digital Health
      • Neurological
      • Patient Monitoring
      • Surgical
      • Orthopedics
    • Top 30 Company Report
    • Expert Insights
    • Slideshows
    • Videos
    • eBook
    • Resources
    • Podcasts
    • Infographics
    • Whitepapers
    • Research
      • White Papers
      • Case Studies
      • Product Spec Sheets
      • Market Data
    • MPO Summit
    • Events
      • Industry Events
      • Live From Show Events
      • Webinars
    • Microsite
      • Companies
      • Product Releases
      • Product Spec Sheets
      • Services
      • White Papers / Tech Papers
      • Press Releases
      • Videos
      • Literature / Brochures
      • Case Studies
    • About Us
      • About Us
      • Contact Us
      • Advertise with Us
      • eNewsletter Archive
      • Privacy Policy
      • Terms of Use
    Columns

    Trump’s 100-Day (Plus) Plan for Medtech M&A

    ...

    Trump’s 100-Day (Plus) Plan for Medtech M&A
    Bryan Hughes, Director, P&M Corporate Finance01.30.17
    Amid much pomp and circumstance, Donald J. Trump has been officially sworn in as the 45th U.S. president, bringing an end to the most inconceivable election cycle in modern history. As Trump’s reign begins, pundits, economists, and ordinary Americans who debated how a polarizing political newcomer beat a seasoned politician have shifted the discussion to understanding what the new administration means for them. 

    Truthfully, any administration change sparks the same questions. When a new CEO is appointed, or a business is acquired, that company’s employees, customers, and suppliers naturally wonder how the change will affect them. Typically, we try to manage the narrative. For example, when a private equity group acquires a medical technology supplier, its investors, consultants, and management teams spend countless hours putting together “100-day plans,” examining every aspect of the organizations and strategizing an agenda for the next chapter in the combined entity’s life. 

    Presidential transitions are no different, albeit on a much grander scale. Everyone, both at home and abroad, is invested in what Trump intends to accomplish in his first 100 days and throughout his term.  Regardless of your political penchant, the ideological and policy differences between the Trump administration and former President Obama are quite clear.

    There are not enough columns available, nor desire on this author’s part, to venture outside the question posed by the headline—how will the Trump administration’s policies affect medical technology merger and acquisition activity over the foreseeable future? As a bit of a disclaimer, while each of the following policy positions may lead to a positive environment for medtech M&A, the downside risk of uncertainty under a president who most are still trying to understand could potentially lead CEOs and corporate boards to hold off on external investments as they seek better clarity. 

    To best understand the potential environment for medical technology transactions, we must step back and examine the specific elements of Trump’s 100-day action plan as outlined in a late October speech. Central to this plan are three main tenets (in the president’s own words)—clean up Washington, protect American workers, and restore security and the constitutional rule of law; as well as a broad legislative agenda. Specifically, several items outlined in that speech will have an impact on healthcare and the medical technology market:
    • Broad easing of federal regulations
    • Renegotiating the North American Free Trade Agreement / Identifying foreign trading abuses
    • Middle Class Tax Relief and Implication Act
    • End the Offshoring Act
    • Repeal and replace the Affordable Care Act
    Taken in aggregate, many industry observers view the new administration as marginally positive for medical technology and the M&A environment. Changes at the executive branch and the Republicans’ control of Congress create conditions generally supportive of a broad platform focused on smaller government, less regulation, and lower taxes—all market forces that may positively impact transaction activity.  

    Economic Policies & Tax Reform
    One of the early topics discussed at the recent J.P. Morgan Healthcare Conference was the potential impact of several changes to the U.S. tax code, which would allow for the repatriation of more than $2 trillion dollars in cash that domestic corporations hold overseas. Johnson & Johnson is likely one of the largest holders of overseas cash, estimated at approximately $40 billion, but many other medical device and pharmaceutical companies hold similarly large amounts. In a fireside chat at the conference, J&J CEO Alex Gorsky suggested “the sun, the moon, and the stars may actually align to bring about significant change,” later hinting that the odds of repatriating that cash have increased under the new administration. Besides an estimated $9 billion tax savings under the new plan, the tactical flexibility provided by the tax change will likely lead J&J to be more aggressive in pursuing M&A transactions as a means to bolster platforms and drive further shareholder growth. Once industry leaders like J&J start down that path, other industry participants presumably will follow.

    It’s not just the tax cuts and repatriated cash that are expected to significantly impact medtech transaction activity—Trump’s tax plan also calls for lowering the corporate levy to 15 percent.  While there is much debate among supporters of the plan, the general goal of driving investment and economic growth is the same. Ironically, these tax changes will cost companies like J&J more, but in aggregate the additional capital not going into government coffers is assumed to drive investment in R&D, new manufacturing facilities, and human capital. In turn, these investments could fuel future M&A.

    Moreover, many corporate executives will gain confidence from the recent stock market performance post-election, and parlay that confidence into a more aggressive deal strategy. A more stimulative fiscal policy (increased infrastructure spending) will further support this confidence as expectations for GDP growth are likely to increase. Inflation will somewhat counter this and may ultimately drive higher interest costs for debt used to fund acquisitions. For the largest transactions, the administration’s position on antitrust issues still needs to be clarified. Although Trump the businessman wrote “The Art of the Deal,” Trump the president has criticized many large healthcare transactions, while several of his Cabinet nominees seem predisposed toward a more market-driven approach.

    Affordable Care Act
    Republicans in the U.S. House of Representatives and U.S. Senate have long made repeal of the Affordable Care Act (ACA) their primary legislative objective. Trump’s healthcare policy proposals have focused on repealing and replacing the ACA, but he has provided few details on what would actually replace it. Rather, his proposals have focused on high-level, free market-based reforms. As such, the two branches’ consolidated view will likely push for elimination of individual and employer mandates and minimum benefit packages, expanding the use of health savings plans and potentially providing Medicaid block grants to states. 

    If the ACA is repealed without replacement mechanisms in place, an estimated 18 million people could lose health insurance. Moreover, Republican support to allow individuals under age 26 to remain on their parents’ insurance, and a ban on denials for pre-existing conditions would put budgetary pressure on any repeal. These realities are prompting Trump and Congressional Republicans to apparently shift toward a more deliberate approach to repeal and replace the ACA. This may take several months to play out and, in the interim, will only create further uncertainty for healthcare deal makers. However, many observers believe that programs started under ACA will continue to gain “free-market steam” and have a larger positive impact than any potential changes from the repeal/replace process. If so, the uncertainty may end up being more detrimental to near-term transaction activity than any potential change itself.

    Medtech Regulatory Environment
    After the nomination of U.S. Congressman and orthopedic surgeon Dr. Tom Price for U.S. Secretary of Health and Human Services (HHS), the Medical Device Manufacturers Association commented: “Medtech innovators continue to deliver on the promise of a better tomorrow, and we will work with Dr. Price to bridge the gap between the regulatory pathways and securing fair reimbursement.” The hope underlying this view is that changes at HHS and the U.S. Food and Drug Administration (FDA) will lead to a “pro-innovation” environment through a more transparent and flexible FDA. The FDA nominee is still unknown, but the consensus on those proposed is each would take a more progressive view to drug and device approvals. While this has generated justified concerns around safety standards, many would consider the reduced regulatory burden as being positive for medtech M&A.

    One of the first orders of business for the Republican-controlled Congress may be permanently repealing the 2.3 percent medical device tax, currently suspended through the end of this year.

    Together with a “pro-innovation” environment, these regulatory changes are likely to spawn new entrepreneurial device companies, which, in turn, will eventually lead to greater M&A opportunities. As Advanced Medical Technology Association President Scott Whitaker shared in a letter to Vice President Mike Pence, “[the] medical device tax has been a significant drag on medical innovation, and resulted in the loss or deferred creation of jobs, reduced research spending, and slowed capital expansion.” A permanent repeal coupled with a more industry-friendly FDA could likely drive continued investment, industry growth, better outcomes for patients, and more deals.

    Trade Policy
    Trump launched his presidential campaign in large part by vowing to bring American jobs back from low-cost regions and getting tough on “unfair” trade deals with China. With an estimated $45 billion of medical products exported versus $54 billion in imports, the United States is a net importer of medical products; thus, any toughening of trade policy may cause some hesitation in M&A activity. 

    In a CNBC commentary piece, Wilbur Ross and Peter Navarro, Trump’s picks for Commerce Secretary and National Trade Council, respectively, suggested that tough negotiations could fix U.S. trade policy. Generally targeting China, the two outlined several objectives of new trade deals, including:
    1. Prompt triggers and automatic renegotiations if trade gains are unfair
    2. Prompt relief against non-tariff barriers
    3. Ironclad sanctions against currency manipulation
    4. No tolerance on IP theft
    5. Stringent environmental, health, and safety standards
    Given their potential impact, however, sweeping tariffs and similar policies would likely face significant challenges before the World Trade Organization, and may hurt U.S. consumers. In all likelihood, the administration will use trade remedy laws to more aggressively enforce current antidumping laws and tariffs. The House tax proposal further complicates matters by advocating for a tax on all U.S. imports, while not taxing exported goods.

    As a whole, 2017 will be an interesting year for the medtech industry and for broader M&A activity. At the intersection of the two, the sweeping changes that are likely to occur will have a lasting impact on investment and transaction activity for medical product suppliers. 


    Bryan Hughes is a director of PMCF and leads the firm’s medical technology team. His practice focuses on assisting clients with mergers and acquisitions, leveraged buyouts, private placements, financings, valuation and strategic consulting. His clients have ranged from global medical technology companies to small, privately held businesses.  
    Related Searches
    • medtech
    • fda
    • 2.3 percent
    • health
    Related Knowledge Center
    • Contract Manufacturing
    Suggested For You
    Heraeus Acquires Mo-Sci Corporation, ETS Technology Holdings Heraeus Acquires Mo-Sci Corporation, ETS Technology Holdings
    MedTech Innovator Names the Finalists for the Title of MedTech Innovator 2021 MedTech Innovator Names the Finalists for the Title of MedTech Innovator 2021
    Babson Diagnostics Raises $31 Million in Series B Funding Babson Diagnostics Raises $31 Million in Series B Funding
    Presidio Medical Names Michael Onuscheck as CEO Presidio Medical Names Michael Onuscheck as CEO
    Vicarious Surgical Business Combination with D8 Holdings Approved Vicarious Surgical Business Combination with D8 Holdings Approved
    Quanta Raises $245 Million in Series D Funding Round Quanta Raises $245 Million in Series D Funding Round
    Luis J. Malavé Joins Integrity Applications Board Luis J. Malavé Joins Integrity Applications Board
    Baxter to Acquire Hillrom in $10.5 Billion Deal Baxter to Acquire Hillrom in $10.5 Billion Deal
    iNitrile iNitrile's Co-Founder Raises $33M for the Company
    Ramin Mousavi Appointed CEO of CathWorks Ramin Mousavi Appointed CEO of CathWorks
    FDA Issues EUA for BD Veritor At-Home Covid-19 Test FDA Issues EUA for BD Veritor At-Home Covid-19 Test
    CVRx Completes First Procedure With Ultrasound-Guided Implant Approach CVRx Completes First Procedure With Ultrasound-Guided Implant Approach
    Stanislav Glezer Joins Inogen as Chief Medical Officer Stanislav Glezer Joins Inogen as Chief Medical Officer
    Glaukos Glaukos' PRESERFLO MicroShunt Approved in Australia
    iCAD Signs Global Distribution Agreement With Sectra iCAD Signs Global Distribution Agreement With Sectra

    Related Breaking News

    • Heraeus Acquires Mo-Sci Corporation, ETS Technology Holdings

      Heraeus Acquires Mo-Sci Corporation, ETS Technology Holdings

      The two deals will strengthen Heraeus' healthcare and medtech portfolio.
      Heraeus 09.22.21

    • MedTech Innovator Names the Finalists for the Title of MedTech Innovator 2021

      MedTech Innovator Names the Finalists for the Title of MedTech Innovator 2021

      Attendees of The MedTech Conference, powered by AdvaMed, will vote for the Grand Prize winner.
      MedTech Innovator 09.21.21

    • Diagnostics
      Babson Diagnostics Raises $31 Million in Series B Funding

      Babson Diagnostics Raises $31 Million in Series B Funding

      Money will be used to help drive commercialization of customer-first, highly accessible diagnostic blood testing.
      Business Wire 09.20.21


    • Presidio Medical Names Michael Onuscheck as CEO

      Presidio Medical Names Michael Onuscheck as CEO

      New chief executive was an executive committee member and president of Global Businesses and Innovation at Alcon.
      Business Wire 09.17.21

    • Surgical
      Vicarious Surgical Business Combination with D8 Holdings Approved

      Vicarious Surgical Business Combination with D8 Holdings Approved

      Vicarious Surgical to debut on NYSE as disruptive next-gen surgical robotics company.
      Business Wire 09.16.21

    Loading, Please Wait..

    Trending
    • FDA Clears LiveMetric's Wearable Blood Pressure Monitoring Tech
    • The Future Of Biomedical Engineering Advancements
    • A New Approach To Post-Market Surveillance
    • Philips Names New Supervisory Board Chairman
    • 7 Steps To Create Your Own Medical Device Marketing Plan
    Breaking News
    • Relay Robotics Adds Three Executives to its Product Team
    • FDA Clears Atalante Hands-Free Self-Balancing Device
    • Kerecis Debuts New Fish-Skin Burn Products
    • Accumold Compliments its Tech Capability With Micro AM
    • Abbott's CardioMEMS HF System Helps Manage Heart Failure
    View Breaking News >
    CURRENT ISSUE

    March 2023

    • Sensing Technology Drives the Future of Medical Care
    • New and Developing Diabetes Technologies Offer 'Sweet Relief'
    • Discussing Matters of Substance in Medtech Materials
    • Medical Device Testers Are Caught Up in a Whirlwind
    • View More >

    Cookies help us to provide you with an excellent service. By using our website, you declare yourself in agreement with our use of cookies.
    You can obtain detailed information about the use of cookies on our website by clicking on "More information”.

    • About Us
    • Privacy Policy
    • Terms And Conditions
    • Contact Us

    follow us

    Subscribe
    Nutraceuticals World

    Latest Breaking News From Nutraceuticals World

    GOOD Meat Receives FDA Go-Ahead for Cultured Meat
    IFF Achieves Industrial-Scale Production of Anaerobic Probiotic Strain
    Jones Healthcare Group Primed to Help Nutraceutical Brands Comply with New Packaging Rules
    Coatings World

    Latest Breaking News From Coatings World

    Orion Debottlenecks Plant in Germany for High-Jetness Carbon Blacks
    Barentz Expands Market Acceleration Team
    Röhm Launches DEGALAN proTerra
    Medical Product Outsourcing

    Latest Breaking News From Medical Product Outsourcing

    Relay Robotics Adds Three Executives to its Product Team
    FDA Clears Atalante Hands-Free Self-Balancing Device
    Kerecis Debuts New Fish-Skin Burn Products
    Contract Pharma

    Latest Breaking News From Contract Pharma

    Hovione, Laxxon Medical Partner on 3D Screen Printed Pharmaceutical Apps
    Stäubli Robotics to Showcase Next Gen Pharma Robots at Interphex 2023
    Remedium, Exothera Partner on Scale-Up, Demonstration Runs for AAV2-FGF18
    Beauty Packaging

    Latest Breaking News From Beauty Packaging

    Wella Company Appoints Frank Smalla as Chief Financial Officer & Chief Operating Officer
    True Botanicals Secures Series B Investment from NextWorld Evergreen
    LVMH Appoints Giulio Bergamaschi as CEO of Acqua di Parma
    Happi

    Latest Breaking News From Happi

    True Botanicals Announces Series B Investment From NextWorld Evergreen
    Rodan + Fields Celebrates 15 Years with Limited-Edition Birthday Box
    Johnson’s Baby Releases Body Wash, Shampoo and Face and Body Cream for Sensitive Skin
    Ink World

    Latest Breaking News From Ink World

    Markem-Imaje Introduces New Hybrid Continuous Inkjet Printer
    Orion Debottlenecks German Facility for High-Jetness Carbon Blacks
    Barentz Expanding Market Acceleration Team
    Label & Narrow Web

    Latest Breaking News From Label & Narrow Web

    Mark Andy introduces ProWORX Label Suite
    Brook + Whittle to install first HP Indigo V12 digital press in US
    HP debuts HP Indigo 200K digital press
    Nonwovens Industry

    Latest Breaking News From Nonwovens Industry

    Berry Releases 2022 Impact Report
    Kimberly-Clark Ranks Third Among 100 Most Sustainable Companies
    Weekly Recap: TerraCycle Launches Diaper Program, Ahlstrom to Divest or Shutter Stenay Plant & More
    Orthopedic Design & Technology

    Latest Breaking News From Orthopedic Design & Technology

    Head and Neck Injury Severity Rising in High School Athletes
    Loci Orthopaedics Earns New Patent for Thumb Base Joint Implant System
    Study: Running Does Not Increase Arthritis Risk
    Printed Electronics Now

    Latest Breaking News From Printed Electronics Now

    NextFlex Launches $4.4 Million Funding Opportunity
    Confidex Partners with Mesh Specialist Wirepas
    Waterman Onions Digitizes Logistics Operation with Zebra

    Copyright © 2023 Rodman Media. All rights reserved. Use of this constitutes acceptance of our privacy policy The material on this site may not be reproduced, distributed, transmitted, or otherwise used, except with the prior written permission of Rodman Media.

    AD BLOCKER DETECTED

    Our website is made possible by displaying online advertisements to our visitors.
    Please consider supporting us by disabling your ad blocker.


    FREE SUBSCRIPTION Already a subscriber? Login